Bristol-Myers beats forecasts, as newer drugs deliver
(Reuters) - Bristol-Myers Squibb Co (BMY.N) reported better than expected quarterly sales and earnings, fueled by strong sales of newer treatments for leukemia, melanoma and diabetes.
The U.S. drugmaker on Thursday said it earned $925 million, or 56 cents per share, in the fourth quarter. That compared with $852 million, or 50 cents per share, in the year-earlier quarter.
(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- Yemeni al Qaeda says attack on hospital was mistake
- Insight: For Chinese farmers, a rare welcome in Russia's Far East